Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
26 August 2018 (14:00 - 18:00)
Organised by:
Abstract
Slides
About the speaker
Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)
5 More presentations in this session
Access the full session
The Event
ESC Congress 2018
26 August 2018
14:00 CET
You may be interested in
Congress Presentation
Congress Presentation
